Mission BioCapital’s Post

We’re thrilled to announce a $161 million Series B financing and the advancement to Phase 2 clinical studies for our lead candidate, NVG-2089! Our lead program, NVG-2089 aims to address high unmet needs for new non-immunosuppressive, efficacious therapies in autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP) and other indications. Thank you to our investors—Sanofi Ventures, Blue Owl Healthcare Opportunities, Norwest Venture Partners, B Capital , Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, funds managed by abrdn Inc., Novo Holdings A/S, Platanus, Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital—for supporting our mission to deliver innovative, non-immunosuppressive therapies for autoimmune diseases. Learn more about this milestone and our progress: https://lnkd.in/gxhqHG_v #inflammation #autoimmunedisease #proteintherapeutics #immunefunction #biotech #bayarea #financing #venturecapital

#PortfolioNews I We're proud to share that we have joined the oversubscribed $135 million series B financing of our #portfolio company Adcendo 👏 💪 After co-leading Adcendo's Series A in 2021 and supporting subsequent extensions that brought the total to €100M, we're proud to join a prominent syndicate of international investors in this new round, reaffirming our commitment to the company and its vision to become a premier ADC company. 🎯 Proceeds will be used to support the advancement of multiple first-in-class #ADC programs into the clinic and through clinical proof of concept. The financing round was led by TCGX, with participation from new investors TPG, OrbiMed Advisors, VENROCK HEALTHCARE CAPITAL PARTNERS LP, Surveyor Capital, and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, HealthCap, Gilde Healthcare and Ysios Capital. 👉 Full details - https://buff.ly/3Z3JfYm #BiotechInvestment #ADCTherapeutics #LifeSciences #VentureCapital #Innovation #Oncology #BiotechFunding #HealthcareInnovation #SeriesBFunding #TransformativeMedicine #ADCResearch #InvestingInScience #BiotechEcosystem #vc

France: Case Study - Amolyt Pharma, a portfolio company of Sofinnova Partners sold to AstraZeneca for $1.05bn. Amolyt Pharma represents a major European VC success story – a French company created and incubated by a pioneering entrepreneur, backed by top European investors, including Sofinnova Partners, who led the company’s €130M series C in 2023, with participation from Intermediate Capital Group (ICG) Tekla Capital Investment LLC, CTI Life Sciences along with existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital. READ the Invest Europe case study here https://lnkd.in/emQzXubz READ the Investors in Healthcare article here https://lnkd.in/ex8GPi53 #lifesciences #venturecapital #healthcare Antoine Papiernik Nicholas Moore Julian Hudson

TPG has closed a $580 million life sciences fund for drug development startups, medical device makers and tech-enabled healthcare services companies. The fund has already backed multiple biotechs, including antibody-drug conjugates maker MBrace Therapeutics, immunology startup Santa Ana Bio, TYK2 drug developer Sudo Biosciences and oncology-focused Bicara Therapeutics, among others. Leading the fund’s investment team are partners Carolyn Ng, Shinichiro Fuse and Lucian Iancovici MD. TPG's Life Sciences Innovation unveiling on Tuesday follows a $650 million fund at Goldman Sachs, a $500 million-plus fund at JP Morgan and about two dozen funds from biotech and life sciences specialists so far this year. More in Endpoints News: #tpg #lifesciences #biotechinvesting #biotech

The right to health is a basic human right 🏥 On #WorldHealthDay, Amolyt Pharma, with backing from Sofinnova Partners, offers hope to patients worldwide suffering from rare endocrine and related diseases. 💫 €212m raised from VCs 💫 Expansion to 50 employees 💫 $1.05bn acquisition agreement with AstraZeneca With support from investors: Intermediate Capital Group (ICG), Tekla Capital Management, CTI Life Sciences Fund, Andera Partners, Novo Ventures, Kurma Partners, EQT Life Sciences, @Innobio 2 (Bpifrance Investissement), Sectoral Asset Management, Pontifax Venture Capital, OrbiMed, Mass General Brigham Ventures, ATEM, Crédit Agricole Création and Relyens Innovation Santé / Turenne Groupe. Read the full story, and take a look at how investment supports Europe’s most innovative healthcare and life sciences businesses ➡️ https://lnkd.in/emQzXubz #PrivateEquity #VentureCapital #SuccessStories #BuildingBetterBusinesses #pharma #healthcare

San Francisco-based Foresite Capital ,led by founder and CEO Jim Tananbaum has closed its sixth fund with $900 million in capital commitments, emphasizing its dedication to advancing healthcare and life sciences technologies. Fund VI has attracted a diverse group of global investors, reflecting strong confidence in Foresite Capital's strategy. The firm will focus on precision therapeutics, life science infrastructure, and healthcare delivery. Founded in 2011, Foresite Capital manages over $3.5 billion in assets and has a notable track record, including 47 IPOs and 58 FDA-approved drugs. The fund's portfolio features promising companies like Alumis and CG Oncology. #ForesiteCapital #HealthcareInvestment #LifeSciences #PrecisionTherapeutics #BiotechInnovation #InvestmentFund #HealthcareDelivery #VentureCapital #FundVI #BiotechInvesting #startup77

Cradle, an Amsterdam-based AI-powered protein engineering platform, raised $73M in Series B funding led by IVP, with participation from Index Ventures and Kindred Capital. Founded and led by CEO Stef van Grieken, Cradle uses machine learning to accelerate the development of therapeutics and bio-based products like enzymes and antibodies, serving customers including Novo Nordisk and Johnson & Johnson. The funds will support platform development, wet lab expansion, and scaling operations. The company also appointed Sam Partovi as Chief Commercial Officer to strengthen its impact in the biotech sector. Learn More: https://lnkd.in/g_xXes6F INVESTORS: IVP, Index Ventures & Kindred Capital ROUND: Series B AMOUNT: $73,000,000 HQ: #Amsterdam #Netherlands #VentureCapital #Cradle #StefvanGrieken #IVP #IndexVentures #KindredCapital #TradedVC

💲🤑☀ A warm and humid week here in the UK, and I know a lot of people are struggling (as we always do in the heat). The good news is the investment market isn't cooling down either, so have a look at my video below for the overview. 🤖 Formation Bio - $372 million series D 🧬 BillionToOne - $130 million series D 💰 Endogenex - $88 million series C 💊 Exsilio Therapeutics - $82 million 💸 VICO Therapeutics B.V. - $70 million series B #financialfridays #biotechinvestment #venturecapitalist #vcinvestment

Goldman Sachs Alternatives has acquired a majority stake in Synthon, a leading platform specializing in the development, manufacturing, and out-licensing of complex generic medicines. This strategic investment will see Goldman Sachs Alternatives partnering with BC Partners and Synthon's management team to further Synthon's mission of providing affordable medicines to patients globally and back Synthon’s next stage of growth, focused on advancing its existing product portfolio and launching new medicines. Our sponsor side leveraged finance team advised Goldman Sachs Alternatives on the financing for its investment. The team was led by partner Nick Hallam together with global co-head of private equity Robin Harvey, alongside senior associate Dhruv Mairal and associates Jack Mellett, Ramone Bedi and Nahima Parvin. Read more here: https://lnkd.in/e2cEvbrA #AOShearman

Goldman Sachs Alternatives has acquired a majority stake in Synthon, a leading platform specializing in the development, manufacturing, and out-licensing of complex generic medicines. This strategic investment will see Goldman Sachs Alternatives partnering with BC Partners and Synthon's management team to further Synthon's mission of providing affordable medicines to patients globally and back Synthon’s next stage of growth, focused on advancing its existing product portfolio and launching new medicines. Our sponsor side leveraged finance team advised Goldman Sachs Alternatives on the financing for its investment. The team was led by partner Nick Hallam together with global co-head of private equity Robin Harvey, alongside senior associate Dhruv Mairal and associates Jack Mellett, Ramone Bedi and Nahima Parvin. Read more here: https://lnkd.in/efP4A369 #AOShearman